Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum NetraMark Holdings Inc AINMF


Primary Symbol: C.AIAI

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several... see more

CSE:AIAI - Post Discussion

NetraMark Holdings Inc > MEND on PurposeInvest's fund + CSO podcast & ALS research
View:
Post by waves1 on Nov 09, 2021 3:00pm

MEND on PurposeInvest's fund + CSO podcast & ALS research

Few notable links on Nurosene Health Inc. ( $MEND $MEND.c ):
 
$MEND has the most portfolio weight in Bruce Campbell's @PurposeInvest small-cap fund.
https://twitter.com/AllStreetsWolf/status/1458138629339959298?s=20
 
CSO Dr. Geraci was featured on the I am a Mortal podcast regarding Nurosene and NetraMark, as well as how AI will shape the future of healthcare
https://open.spotify.com/show/1aX9zM67UVN5tv19v7GsDw?si=nVy0bg4zS0u2ZosF6R6NTw
 
Plus, Dr. Geraci is presenting his research on ALS at the EndALS Pitch Day hosted by a data science subsidiary of Google today. He was requested to help prepare genetic data to discover a set of new drug targets and repurpose candidates for ALS patients.
https://finance.yahoo.com/news/nurosenes-chief-scientific-officer-dr-140000074.html
 
$MEND is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. As the global market size for mobile health applications (mHealth) is expected to reach USD $310 billion by 2027, $MEND has the ability to capitalize off its upcoming growth and is likely to do so.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities